Metraipolis › archive › dc_030a80529964

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response — Europe PMC PMID:37958355

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/37958355
DOI
10.3390/cancers15215181
License (as archived)
solo-consultazione
Archived
2026-10-06T10:20:51.465Z
SHA-256 of the archived text
50563ef6d766148b938860da8a161f5f9164169b6ac50de3aa5c639b20ee5660
Stable URL of this page
https://metraipolis.com/documento/dc_030a80529964

How to cite

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response — Europe PMC PMID:37958355 — Europe PMC (en), https://europepmc.org/article/MED/37958355 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_030a80529964 (Metraipolis archive dc_030a80529964, sha256 50563ef6d766148b938860da8a161f5f9164169b6ac50de3aa5c639b20ee5660)
BibTeX
@misc{dc030a80529964,
  title = {Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response — Europe PMC PMID:37958355},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/37958355},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_030a80529964; sha256 50563ef6d766148b938860da8a161f5f9164169b6ac50de3aa5c639b20ee5660},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/37958355. Agents can read the archived copy with the MCP tool read_document.